Picture: Deep Bhandari led session at ACG – MedicinMan Pharma Marketing in the New Age Seminar – Prashant Pathak, Annapurna Das, Prasant Mohanty, Ramesh Juneja ACG Executive, Vivek Kamath and Anup Soans
With over three decades in healthcare leadership, Kamath to steer India’s only end-to-end plasma products company into its next phase of growth.
Plasmagen Biosciences, a leading Indian biopharmaceutical company specializing in blood plasma–derived pharmaceutical products, has announced the appointment of Vivek V. Kamath as its Chief Executive Officer, effective October 6, 2025.
Plasmagen, which began commercial operations at its state-of-the-art plasma fractionation facility in 2024, has quickly emerged as South Asia’s only fully integrated, pure-play plasma products company. The firm’s mission is to deliver high-quality plasma-derived therapies that address critical patient needs in India and emerging markets.
A Proven Leader with Global Healthcare Experience
Vivek V. Kamath brings over 30 years of leadership experience across pharmaceuticals, over-the-counter (OTC) products, and diagnostics. He has held senior management roles across India, South Asia, and Southeast Asia, including as Managing Director of Abbott India Ltd., Abbott Healthcare Ltd., and MSD Pharmaceuticals (South Asia).
Beyond his corporate roles, Kamath has served as a strategic advisor to private equity funds, helping scale and professionalize healthcare portfolio companies across emerging markets. His appointment reflects Plasmagen’s commitment to building globally benchmarked governance, operational excellence, and patient-centric innovation.
Strategic Vision from the Founder’s Desk
Vinod Nahar, Founder and now Executive Chairman of Plasmagen Biosciences, said: “Plasmagen’s mission is to become a trusted and leading Indian biopharmaceutical company that improves the health and quality of life of patients globally. Vivek’s deep experience in leading large organisations, coupled with his operational expertise and ability to build world-class teams, makes him an outstanding addition to our leadership team.”
With Kamath taking the CEO mantle, Nahar transitions into a strategic leadership role, focusing on long-term vision, innovation, and global expansion.
A CEO’s Vision for Purpose-Driven Growth
Accepting his new role, Vivek V. Kamath said: “Plasmagen’s combination of world-class manufacturing and a purpose-driven leadership team has created a remarkable foundation for growth. I am privileged to join the company at this pivotal stage and look forward to working with Vinod and our colleagues in shaping the next chapter—anchored in innovation, quality, and care that reaches patients globally.”
A Strengthened Leadership Team for Expansion
As part of its next phase of growth, Plasmagen has expanded its leadership team with key appointments:
Sethu Madhavan – Chief Operating Officer (Manufacturing & Technical Operations)
Arnav Jain – Chief Financial Officer
This strengthened executive structure will drive sustainable growth, expand market reach, and accelerate Plasmagen’s journey toward becoming a global leader in plasma-derived biotherapeutics.
Editorial Insight: Why This Appointment Matters
Vivek Kamath’s appointment marks a strategic inflection point not only for Plasmagen but also for India’s emerging biopharma ecosystem. His proven record in steering multinational healthcare operations positions him to blend global best practices with local innovation — a crucial ingredient as India strengthens its position in complex biologics and plasma-based therapies.
Plasmagen’s rise also highlights how Indian firms are transitioning from dependency on imports to becoming self-reliant producers of high-value biotherapeutics — a trend aligned with national health priorities and global quality benchmarks.
Editor’s Note | The Next Chapter for Indian Biopharma Leadership
The appointment of Vivek V. Kamath at Plasmagen reflects a broader leadership shift within Indian healthcare and life sciences — where seasoned professionals from global pharma are now driving innovation-led Indian enterprises.
This trend signals growing investor confidence in India’s scientific capabilities, manufacturing depth, and leadership maturity. Companies like Plasmagen are redefining the sector by building indigenous capacity for advanced therapies, while ensuring global quality, patient trust, and ethical growth remain at the center of their journey.
As Indian biopharma moves toward greater self-sufficiency and international relevance, such leadership transitions will be pivotal in shaping the country’s biotherapeutic future.
